110 related articles for article (PubMed ID: 21645967)
1. Sunitinib in urothelial cancer: clinical, pharmacokinetic, and immunohistochemical study of predictors of response.
Gallagher DJ; Al-Ahmadie H; Ostrovnaya I; Gerst SR; Regazzi A; Garcia-Grossman I; Riches J; Gounder SK; Flaherty AM; Trout A; Milowsky MI; Bajorin DF
Eur Urol; 2011 Aug; 60(2):344-9. PubMed ID: 21645967
[TBL] [Abstract][Full Text] [Related]
2. Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma.
Grivas PD; Daignault S; Tagawa ST; Nanus DM; Stadler WM; Dreicer R; Kohli M; Petrylak DP; Vaughn DJ; Bylow KA; Wong SG; Sottnik JL; Keller ET; Al-Hawary M; Smith DC; Hussain M
Cancer; 2014 Mar; 120(5):692-701. PubMed ID: 24249435
[TBL] [Abstract][Full Text] [Related]
3. Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma.
Motzer RJ; Hutson TE; Hudes GR; Figlin RA; Martini JF; English PA; Huang X; Valota O; Williams JA
Cancer Chemother Pharmacol; 2014 Oct; 74(4):739-50. PubMed ID: 25100134
[TBL] [Abstract][Full Text] [Related]
4. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.
Rini BI; Michaelson MD; Rosenberg JE; Bukowski RM; Sosman JA; Stadler WM; Hutson TE; Margolin K; Harmon CS; DePrimo SE; Kim ST; Chen I; George DJ
J Clin Oncol; 2008 Aug; 26(22):3743-8. PubMed ID: 18669461
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of pazopanib as second-line treatment after sunitinib in patients with metastatic renal cell carcinoma: a Southern China Urology Cancer Consortium Trial.
Xie M; He CS; Huang JK; Lin QZ
Eur J Cancer; 2015 Mar; 51(5):595-603. PubMed ID: 25618828
[TBL] [Abstract][Full Text] [Related]
6. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
La Vine DB; Coleman TA; Davis CH; Carbonell CE; Davis WB
Am J Clin Oncol; 2010 Jun; 33(3):217-20. PubMed ID: 19745694
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the prognostic significance of altered mammalian target of rapamycin pathway biomarkers in upper tract urothelial carcinoma.
Bagrodia A; Krabbe LM; Gayed BA; Kapur P; Bernstein I; Xie XJ; Wood CG; Karam JA; Weizer AZ; Raman JD; Remzi M; Rioux-Leclerq N; Haitel A; Roscigno M; Bolenz C; Bensalah K; Sagalowsky AI; Shariat SF; Lotan Y; Margulis V
Urology; 2014 Nov; 84(5):1134-40. PubMed ID: 25443916
[TBL] [Abstract][Full Text] [Related]
8. Sunitinib malate for the treatment of renal cell carcinoma.
Wood L
Expert Opin Pharmacother; 2012 Jun; 13(9):1323-36. PubMed ID: 22607009
[TBL] [Abstract][Full Text] [Related]
9. A phase II study of sunitinib in patients with recurrent and/or metastatic non-nasopharyngeal head and neck cancer.
Fountzilas G; Fragkoulidi A; Kalogera-Fountzila A; Nikolaidou M; Bobos M; Calderaro J; Andreiuolo F; Marselos M
Cancer Chemother Pharmacol; 2010 Mar; 65(4):649-60. PubMed ID: 19655144
[TBL] [Abstract][Full Text] [Related]
10. Hypoxia-inducible factor and mammalian target of rapamycin pathway markers in urothelial carcinoma of the bladder: possible therapeutic implications.
Tickoo SK; Milowsky MI; Dhar N; Dudas ME; Gallagher DJ; Al-Ahmadie H; Gopalan A; Fine SW; Ishill N; Bajorin DF; Reuter VE
BJU Int; 2011 Mar; 107(5):844-849. PubMed ID: 20707797
[TBL] [Abstract][Full Text] [Related]
11. Response rates and adverse effects of continuous once-daily sunitinib in patients with advanced renal cell carcinoma: a single-center study in Turkey.
Yildiz I; Sen F; Basaran M; Ekenel M; Agaoglu F; Darendeliler E; Tunc HM; Ozcan F; Bavbek S
Jpn J Clin Oncol; 2011 Dec; 41(12):1380-7. PubMed ID: 22013228
[TBL] [Abstract][Full Text] [Related]
12. Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure.
George S; Blay JY; Casali PG; Le Cesne A; Stephenson P; Deprimo SE; Harmon CS; Law CN; Morgan JA; Ray-Coquard I; Tassell V; Cohen DP; Demetri GD
Eur J Cancer; 2009 Jul; 45(11):1959-68. PubMed ID: 19282169
[TBL] [Abstract][Full Text] [Related]
13. Bronchial involvement in advanced stage lymphangioleiomyomatosis: histopathologic and molecular analyses.
Hayashi T; Kumasaka T; Mitani K; Okada Y; Kondo T; Date H; Chen F; Oto T; Miyoshi S; Shiraishi T; Iwasaki A; Hara K; Saito T; Ando K; Kobayashi E; Gunji-Niitsu Y; Kunogi M; Takahashi K; Yao T; Seyama K
Hum Pathol; 2016 Apr; 50():34-42. PubMed ID: 26997436
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of sunitinib in patients with metastatic urothelial cancer.
Gallagher DJ; Milowsky MI; Gerst SR; Ishill N; Riches J; Regazzi A; Boyle MG; Trout A; Flaherty AM; Bajorin DF
J Clin Oncol; 2010 Mar; 28(8):1373-9. PubMed ID: 20142593
[TBL] [Abstract][Full Text] [Related]
15. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
[TBL] [Abstract][Full Text] [Related]
16. Serum C-Telopeptide Collagen Crosslinks and Plasma Soluble VEGFR2 as Pharmacodynamic Biomarkers in a Trial of Sequentially Administered Sunitinib and Cilengitide.
O'Donnell PH; Karovic S; Karrison TG; Janisch L; Levine MR; Harris PJ; Polite BN; Cohen EE; Fleming GF; Ratain MJ; Maitland ML
Clin Cancer Res; 2015 Nov; 21(22):5092-9. PubMed ID: 26199386
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity.
Bellmunt J; González-Larriba JL; Prior C; Maroto P; Carles J; Castellano D; Mellado B; Gallardo E; Perez-Gracia JL; Aguilar G; Villanueva X; Albanell J; Calvo A
Ann Oncol; 2011 Dec; 22(12):2646-2653. PubMed ID: 21427062
[TBL] [Abstract][Full Text] [Related]
18. Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial.
Necchi A; Mariani L; Zaffaroni N; Schwartz LH; Giannatempo P; Crippa F; Morosi C; Lanocita R; Sava T; Ortega C; Messina C; Sacco C; Pennati M; Daidone MG; Nicolai N; De Braud F; Gianni AM; Salvioni R
Lancet Oncol; 2012 Aug; 13(8):810-6. PubMed ID: 22819172
[TBL] [Abstract][Full Text] [Related]
19. Bridging Sunitinib Exposure to Time-to-Tumor Progression in Hepatocellular Carcinoma Patients With Mathematical Modeling of an Angiogenic Biomarker.
Ait-Oudhia S; Mager DE; Pokuri V; Tomaszewski G; Groman A; Zagst P; Fetterly G; Iyer R
CPT Pharmacometrics Syst Pharmacol; 2016 Jun; 5(6):297-304. PubMed ID: 27300260
[TBL] [Abstract][Full Text] [Related]
20. Significance of 4E-binding protein 1 as a therapeutic target for invasive urothelial carcinoma of the bladder.
Nishikawa M; Miyake H; Behnsawy HM; Fujisawa M
Urol Oncol; 2015 Apr; 33(4):166.e9-15. PubMed ID: 25618298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
